The April 2010 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper:
Volume 16, Issue 2
Legal and Regulatory Updates
|Legal and regulatory update||PDF|
|Gerry Kamstra, John Wilkinson|
|Funding the dream at the Mid-Atlantic Biotech Conference||PDF|
As promised, I have posted my observations from the 2009 Kyoto Prize. I had an opportunity to interact with each of the laureates, and focused on the question of how they were able to accomplish their exemplary achievements. It is not enough to simply be brilliant or hard-working — all their peers likely share these characteristics. What are the differentiating factors that enabled their unique achievements?
My observations appear in the latest issue of the Journal of Commercial Biotechnology, and are available for viewing without subscription.
I was recently queried by the Israeli Life Science Industry on my thoughts regarding trends in the global biotechnology industry as well as elements of specific interest to Israel. You can see my full interview at ILSI’s website.
The next DCbiotech meeting will be at the Redwood Restaurant and Bar in Bethesda, MD on April 14th 2010. Redwoods is at 7121 Bethesda Ave, and we’ll be meeting in the bar area from 6-8pm. To facilitate finding the group, you may want to check out my photo on the about page.
Also, we will have a special guest. John Avellanet, frequent BiotechBlog contributor and author of the upcoming book Get to Market Now! will be in attendance. A limited number of books will be available for signing and sale.
Drug Patent Expirations in April 2010
*Drugs may be covered by multiple patents
|Tradename||Applicant||Generic Name||Patent Number|| Patent Expiration|
|HYZAAR||Merck||hydrochlorothiazide; losartan potassium||5,153,197*PED||Apr 6, 2010|
|IPLEX||Insmed||mecasermin rinfabate recombinant||5,200,509||Apr 6, 2010|
|COZAAR||Merck||losartan potassium||5,153,197*PED||Apr 6, 2010|
|DUODOTE||Meridian Medcl||atropine; pralidoxime chloride||5,092,843||Apr 12, 2010|
|EMBEDA||Alpharma King||morphine sulfate; naltrexone hydrochloride||5,202,128||Apr 13, 2010|
|KADIAN||Actavis Elizabeth||morphine sulfate||5,202,128||Apr 13, 2010|
|MUSE||Vivus||alprostadil||5,773,020||Apr 25, 2010|
|FLOMAX||Boehringer Ingelheim||tamsulosin hydrochloride||4,703,063*PED||Apr 27, 2010|
This information is also available in an email newsletter: Subscribe to the DrugPatentWatch Patent Expiration Bulletin.Courtesy of DrugPatentWatch.com